Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Retrophin, Inc. Is Tanking Today

TheMotleyFool

0 0

Shares of the orphan drug specialist Retrophin (NASDAQ: RTRX) are down by 25.3% as of 12:44 p.m. EDT today. The culprit?

Retrophin's shares are sinking on the news that the pantothenate kinase-associated neurodegeneration (PKAN) drug candidate, fosmetpantotenate, failed to meet its primary and secondary endpoints in a pivotal trial. PKAN is an ultra-rare nervous system disorder that results in a range of movement abnormalities.

Image Source: Getty Images.

Source Fool.com

Like: 0

RTRX

Share